Samsung Biologics has secured its first biopharmaceutical production base in the United States, bolstering its capabilities as a global contract development and manufacturing organization (CDMO). This strategic move aims to enhance responsiveness to North American clients while strengthening supply chain stability.
On Monday, Samsung Biologics announced the signing of an acquisition agreement with GlaxoSmithKline (GSK) for the Human Genome Sciences (HGS) biopharmaceutical production facility in Rockville, Maryland.
The deal involves Samsung Biologics America, the company’s U.S. subsidiary. purchasing the asset for 280 million USD. The asset acquisition is scheduled to be completed by the first quarter of 2026.
The Rockville facility, situated in a prominent U.S. biotech hub, is a drug substance (DS) production plant with a total capacity of 60,000 liters. With two manufacturing buildings, it is equipped to support antibody drug production across various scales, from clinical trials to commercial manufacturing.
This acquisition allows Samsung Biologics to inherit existing production contracts, securing a stable pipeline of large-scale contract manufacturing orders. The company will also retain approximately 500 local employees, ensuring continuity in operations and expertise.
Looking ahead, Samsung Biologics plans to explore additional investments, including potential capacity expansions, based on medium to long-term demand forecasts and operational needs. The goal is to transform the facility into a long-term growth engine in the North American market.
With this move, Samsung Biologics establishes a dual production system spanning its main hub in Songdo, South Korea, and the new site Rockville, USA.
The plan is to provide global customers with more flexible and reliable production options by distributing production bases by region, expand collaborations with North American partners, and enhance resilience against geopolitical risks and supply chain disruptions.
John Rim, CEO of Samsung Biologics, stated, “This acquisition represents our strategic commitment to strengthening U.S. manufacturing capabilities and advancing the global healthcare industry. We will work closely with federal, state, and local stakeholders to enhance customer support and ensure stable biopharmaceutical supply. Our collaboration with the experienced local workforce will continually boost the Rockville facility’s competitiveness.”
GSK also views the deal as a boon for global supply chain stability. Regis Simard, GSK’s Global Supply Chain President, commented, “Samsung Biologics’ acquisition of the Rockville facility ensures continued domestic production of vital medicines for U.S. patients. This move will enhance GSK’s operational stability and responsiveness within our global supply network.”
The industry evaluates this acquisition as a turning point for Samsung Biologics, marking its evolution from an Asia-centric production base to a truly global player with significant North American manufacturing capabilities.
The U.S. production foothold is expected to be crucial in winning contracts, especially as demands from major North American pharmaceutical clients continue to rise.
